1. Home
  2. HQH vs REPL Comparison

HQH vs REPL Comparison

Compare HQH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HQH
  • REPL
  • Stock Information
  • Founded
  • HQH 1986
  • REPL 2015
  • Country
  • HQH United States
  • REPL United States
  • Employees
  • HQH N/A
  • REPL N/A
  • Industry
  • HQH Finance Companies
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HQH Finance
  • REPL Health Care
  • Exchange
  • HQH Nasdaq
  • REPL Nasdaq
  • Market Cap
  • HQH 936.3M
  • REPL 780.3M
  • IPO Year
  • HQH N/A
  • REPL 2018
  • Fundamental
  • Price
  • HQH $17.89
  • REPL $14.01
  • Analyst Decision
  • HQH
  • REPL Strong Buy
  • Analyst Count
  • HQH 0
  • REPL 6
  • Target Price
  • HQH N/A
  • REPL $19.67
  • AVG Volume (30 Days)
  • HQH 183.8K
  • REPL 816.7K
  • Earning Date
  • HQH 01-01-0001
  • REPL 02-14-2025
  • Dividend Yield
  • HQH 11.56%
  • REPL N/A
  • EPS Growth
  • HQH N/A
  • REPL N/A
  • EPS
  • HQH 1.09
  • REPL N/A
  • Revenue
  • HQH N/A
  • REPL N/A
  • Revenue This Year
  • HQH N/A
  • REPL N/A
  • Revenue Next Year
  • HQH N/A
  • REPL $300.41
  • P/E Ratio
  • HQH $15.24
  • REPL N/A
  • Revenue Growth
  • HQH N/A
  • REPL N/A
  • 52 Week Low
  • HQH $14.31
  • REPL $4.92
  • 52 Week High
  • HQH $17.94
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • HQH 63.85
  • REPL 62.26
  • Support Level
  • HQH $17.82
  • REPL $13.33
  • Resistance Level
  • HQH $18.28
  • REPL $14.52
  • Average True Range (ATR)
  • HQH 0.20
  • REPL 0.93
  • MACD
  • HQH 0.09
  • REPL 0.22
  • Stochastic Oscillator
  • HQH 74.43
  • REPL 85.16

About HQH abrdn Healthcare Investors Shares of Beneficial Interest

abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Share on Social Networks: